ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Nephritis"

  • Abstract Number: 0631 • ACR Convergence 2024

    Impact of Baseline Proteinuria Level on Long-term Outcomes in Lupus Nephritis

    Fadi Kharouf1, Qixuan Li2, Laura Patricia Whittall Garcia2, Dafna Gladman3 and Zahi Touma4, 1University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, 2University Health Network, Toronto, ON, Canada, 3University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 4University of Toronto, Toronto, ON, Canada

    Background/Purpose: Proteinuria is a marker of lupus nephritis (LN) activity, damage, and response to therapy. There is still sparse evidence on the renal outcomes associated…
  • Abstract Number: 0650 • ACR Convergence 2024

    Tubulointerstitial Inflammation Predicts Tubular Atrophy, Fibrosis, and Renal Function Loss in Lupus Nephritis

    Yevgeniya Gartshteyn1, Laura Geraldino2, Shuwei Wang3, Vivette D'Agati1 and Robert Winchester1, 1Columbia University Irving School of Medicine, New York, NY, 2Division of Rheumatology, Department of Medicine, Columbia University, New York, NY, 3Rutgers New Jersey Medical School, Newark, NJ

    Background/Purpose:     Current classification criteria of lupus nephritis (LN) emphasize glomerular pathology, however tubular atrophy and interstitial fibrosis (TAIF) are better predictors of poor…
  • Abstract Number: 1536 • ACR Convergence 2024

    Prescription Rates of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Lupus Nephritis: A Comparative Study Across Specialties

    JM JANSZ1, EA Troy2, WL Galanter3, Elaine Adams4, Nadera Sweiss5 and HJ CHANG6, 1University of Illinois at Chicago, Chicago, IL, 2University of Illinois at Chicago, Woodridge, IL, 3University of Illinois at Chicago; Jesse Brown VA Medical Center, CHICAGO, IL, 4Jesse Brown VA Medical Center, La Grange, IL, 5University of IL, Chicago, IL, 6RHEUMATOLOGIST, CHICAGO, IL

    Background/Purpose: Lupus nephritis is a well-known and severe complication in patients with systemic lupus erythematosus (SLE) that can lead to significant morbidity and mortality. Angiotensin-converting…
  • Abstract Number: 1556 • ACR Convergence 2024

    Efficacy and Safety of Anifrolumab Across Organ Domains of Systemic Lupus Erythematosus. A Systematic Review and Meta-Analysis

    Mohammad Taha1, Yomna W Mahmoud1, Mohammad Ramadan1, sarah nasir1, Mariam salah1, Yassin shenawy2, doaa gadelrab1 and Muhammad abuawwad1, and ARC team, 1Cairo university, Cairo, Egypt, 2cairo, cairo, Egypt

    Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease affecting multiple organ systems. Anifrolumab is a monoclonal antibody that antagonizes type I interferon receptors,…
  • Abstract Number: 1642 • ACR Convergence 2024

    A Urinary Biomarker Panel to Predict the Probability of Histologically Active Lupus Nephritis

    Andrea Fava1, Andrew Concoff2, Tyler O'Malley3, Sepehr Taghavi4, Touba Warsi4, Sudha Kumar4, Christine Schleif4 and Michelle Petri5, 1Divison of Rheumatology, Johns Hopkins University, Baltimore, MD, 2Exagen, Inc., Los Angeles, CA, 3Exagen, Vista, CA, 4Exagen, Carlsbad, CA, 5Johns Hopkins University School of Medicine, Timonium, MD

    Background/Purpose: Achieving an NIH Activity Index of < 2 upon treatment is associated with less LN flare and thus better long-term kidney survival. Here, we…
  • Abstract Number: 1685 • ACR Convergence 2024

    The Renal Activity Index for Lupus (RAIL) Identifies Active Renal Disease in SLE Patients and Its Longitudinal Score Associates with Achievement of Renal Responses in Lupus Nephritis

    Minal Aundhia1, Jinqi Liu2, Ellen Cody3, James Rose4, Angela Merritt1, Megan Quinlan-Waters1, Alyssa Sproles5, Sherry Thornton5, Prasad Devarajan4, Bin Huang6 and hermine brunner7, 1Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Bristol Myers Squibb, Princeton, NJ, 3Children's Wisconsin, Milwaukee, 4Cincinnati Children's Hospital Medical Center, Cincinnati, 5Cincinnati Children's Hospital, Cincinnati, 6Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cinciannati, OH, 7Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH

    Background/Purpose: Lupus Nephritis (LN) confers a poor prognosis, and there is a lack of effective non-invasive tests to assess disease activity and treatment response. We…
  • Abstract Number: 1787 • ACR Convergence 2024

    Linking Transcriptomic Profiles of Kidney and Blood Samples Provides Insight into Identification of Lupus Nephritis

    Andrea Daamen1, Kathryn Kingsmore2, Prathyusha Bachali3, Nan Shen4, Amrie Grammer5 and Peter Lipsky1, 1AMPEL BioSolutions, Charlottesville, VA, 2AMPEL BioSolutions, Charlottesville, 3AMPEL BioSolutions, Redmond, WA, 4Shanghai Institute of Rheumatology, Renji Hospital, Shanghai Jaiotong University School of Medicine, Shanghai, CN, Shanghai, China (People's Republic), 5AMPEL LLC, Charlottesville, VA

    Background/Purpose: Current clinical methods to diagnose and evaluate the severity of lupus nephritis (LN) rely on identification of kidney dysfunction followed by invasive kidney biopsies.…
  • Abstract Number: 1798 • ACR Convergence 2024

    CXCL6 Synthesized by Proximal Tubule Cells May Promote Fibrosis in Lupus Nephritis

    Philip Carlucci1, Nalani Sachan2, Andrea Fava3, Brooke Cohen2, Jasmine Shwetar4, Siddarth Gurajala5, Qian Xiao5, Joseph Mears6, Katie Preisinger2, Devyn Zaminski7, Kristina Deonaraine8, Peter Izmirly9, Judith James10, Joel Guthridge10, Wade DeJager11, David Wofsy12, Cynthia Loomis2, Gyles Ward2, Ming Wu13, Chaim Putterman14, Deepak Rao15, Betty Diamond16, Derek Fine17, Jose Monroy-Trujillo17, H Michael Belmont7, William Apruzzese18, Anne Davidson19, Richard Furie20, Paul Hoover21, Celine Berthier22, Maria Dall'Era23, Diane Kamen24, Kenneth Kalunian25, Jennifer Anolik26, Jennifer Barnas27, Arnon Arazi28, Soumya Raychaudhuri29, Nir Hacohen30, Robert Clancy31, Kelly Ruggles32, Michelle Petri33 and Jill Buyon2, and the Accelerating Medicines Partnership in RA/SLE, 1New York University School of Medicine, New York, NY, 2NYU Grossman School of Medicine, New York, NY, 3Johns Hopkins University, Baltimore, MD, 4New York School of Medicine, Ann Arbor, MI, 5Harvard Medical School, Boston, MA, 6Michigan University, Ann Arbor, MI, 7NYU School of Medicine, New York, NY, 8Jacobs School of Medicine, University at Buffalo, Buffalo, NY, 9New York University Grossman School of Medicine, New York, NY, 10Oklahoma Medical Research Foundation, Oklahoma City, OK, 11Oklahoma Medical Research Foundation, Oklahoma City, 12University of California San Francisco, SF, CA, 13Northwell, New York, NY, 14Albert Einstein College of Medicine, Safed, Israel, 15Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 16The Feinstein Institutes for Medical Research, Manhasset, NY, 17Johns Hopkins School of Medicine, Baltimore, MD, 18Brigham and Women's Hospital, Everett, MA, 19Feinstein Institutes for Medical Research, Manhasset, NY, 20Northwell Health, Manhasset, NY, 21Brigham and Women's Hospital, SWAMPSCOTT, MA, 22University of Michigan, Ann Arbor, MI, 23UCSF, Corte Madera, CA, 24Medical University of South Carolina, Charleston, SC, 25University of California San Diego, La Jolla, CA, 26University of Rochester Medical Center, Rochester, NY, 27University of Rochester, Rochester, NY, 28Feinstein Institutes for Medical Research, Melrose, MA, 29Brigham and Women's Hospital, Boston, MA, 30Broad Institute of MIT and Harvard, Boston, MA, 31Columbia University Medical Center, New York, NY, 32NYU Grossman School of Medicine, Brooklyn, NY, 33Johns Hopkins University School of Medicine, Timonium, MD

    Background/Purpose: Detection of urinary CXCL6, a member of the IL-8 chemokine family, has been linked to CKD and is a proposed marker of chronic damage…
  • Abstract Number: 1808 • ACR Convergence 2024

    Not Only Type-I Interferon Regulated Genes Are Differentially Expressed in Circulating Monocytes from Active Lupus Nephritis Patients

    Paula Losada Vanegas1, Juan Antonio Villatoro-García2, Daniel Rodriguez3, Juan Camilo Diaz3, Ricardo Pineda4, Pedro Carmona-Saez5, Mauricio Rojas6 and Gloria Vasquez7, 1Universidad de Antioquia, Medellin, Antioquia, Colombia, 2GENYO (Centre for Genomics and Oncological Research: Pfizer, University of Granada, Granada, Andalucia, Spain, 3ARTMEDICA, Medellín, Antioquia, Colombia, 4ARTMEDICA, Medellin, Antioquia, Colombia, 5GENYO (Centre for Genomics and Oncological Research: Pfizer, University of Granada, Granada, Asturias, Spain, 6Grupo de Inmunología Celular e Inmunogenética, Sede de Investigación Universitaria. Facultad de Medicina. Universidad de Antioquia, Medellin, Antioquia, Colombia, 7Grupo de Inmunología Celular e Inmunogenética, Sede de Investigación Universitaria. Facultad de Medicina.Universidad de Antioquia, Medellin, Colombia

    Background/Purpose: Monocytes play an important role in organ damage, such as in Lupus Nephritis (LN). Although monocytes are typically considered inflammatory cells, evidence shows they…
  • Abstract Number: 1860 • ACR Convergence 2024

    Targeting Th1 Effector Cytokines, TNF-α and IFN-γ, Attenuates Experimental Autoimmune Myeloperoxidase ANCA Associated Vasculitis

    Kei Nagai1, Daniel Koo Yuk Cheong2, Anh Cao-Le2, Joshua Ooi3 and Poh Yi Gan2, 1Department of Nephrology, University of Tsukuba, Tsukuba, Ibaraki, Japan, 2Department of Medicine, Monash University, Melbourne, Victoria, Australia, 3Monash University-T Cell Therapies Research Group, Clayton, Victoria, Australia

    Background/Purpose: Anti-cytokine monoclonal antibody (mAb) therapies have shown efficacy in numerous autoimmune diseases but have yet to succeed in myeloperoxidase anti-neutrophil cytoplasmic antibody associated vasculitis…
  • Abstract Number: 2381 • ACR Convergence 2024

    Clinical Characteristics, Readmission Rates, and Outcomes in Lupus Patients with and Without Nephritic Involvement: Analysis from a National Database

    Kishan Patel1, Shivang Chaudhary2, Simran Bhimani3, Yash Deshpande3, Leighton Hope2 and Chaitanya Rojulpote2, 1Riverside Community Hospital, Riverside, CA, 2Saint Louis University, St. Louis, MO, 3The Wright Center for graduate medical education, Scranton, PA

    Background/Purpose: Lupus nephritis (LN) is a complication of systemic lupus erythematosus (SLE) that occurs in 50 percent of patients. LN serves as an important predictor…
  • Abstract Number: 2387 • ACR Convergence 2024

    Biomarkers of Lupus Nephritis Are Less Predictive in APOL1 High Risk Genotype Lupus

    Madeline Alizadeh1, Vishnuprabu Pandian1, Christele Felix2, Andrra Nimoni2, Jasmin Divers3, Timothy Niewold2 and Ashira Blazer1, 1University of Maryland Baltimore, Baltimore, MD, 2Hospital for Special Surgery, New York, NY, 3NYU School of Medicine, New York, NY

    Background/Purpose: Compared to Apolipoprotein L1 (APOL1) low risk genotype (LRG) patients, APOL1 (HRG) has been shown to increase the risk of chronic kidney disease in…
  • Abstract Number: 2498 • ACR Convergence 2024

    The Methylome Profile of B-cells as a Biomarker of Nephritis in IgA Vasculitis

    Veronica Pulito-Cueto1, Joao Carlos Batista-Liz1, Laura Carmen Terron2, Iván Fernández Rengel3, María Sebastián Mora-Gil4, María Teresa Leonardo5, Ana Peñalba5, Luis Martín-Penagos6, Lara Belmar-Vega7, Cristina Gomez-Fernandez8, Ligia Gabrie-Rodriguez9, Rafael Gálvez Sánchez9, Luis Caminal-Montero10, Ana Turrion Nieves11, Patricia Quiroga Colina12, Esther Vicente-rabaneda13, Belén Sevilla-Pérez14, José Luis Callejas15, Eduardo Andrés-León2, Javier Martin16, Ana María Marquez17, Santos Castañeda13, Ricardo Blanco-Alonso18 and Raquel Lopez-mejias1, 1IDIVAL, Santander, Spain, 2Unidad de Bioinformática, Instituto de Parasitología y Biomedicina ‘López-Neyra’, CSIC, Granada, Spain, 3Bioinformatics Unit, Institute of Parasitology and Biomedicine López-Neyra (IPBLN), CSIC, GENYO, Cen, Granada, Spain, 4Immunopathology Group, IDIVAL, Santander, Spain, 5Division of Pediatrics, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 6Immunopathology Group, IDIVAL. Division of Nephrology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 7Immunopathology Group, IDIVAL. Division of Nephrology, Hospital Universitario Marqués de Valdecilla, Santander, 8Division of Dermatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 9Immunopathology Group, IDIVAL. Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 10Internal Medicine Department, Hospital Universitario Central de Asturias, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain, 11Rheumatology Department, Hospital Universitario Virgen de la Vega, Salamanca, Spain, 12Division of Rheumatology, Hospital Universitario de La Princesa, Madrid, Spain, 13Hospital Universitario de La Princesa, Madrid, Spain, 14Division of Pediatrics, Hospital Universitario San Cecilio, Granada, Spain, 15Systemic Autoimmune Diseases Unit, Hospital Clinico San Cecilio, Instituto de Investigación Biosanitaria de Granada ibs.GRANADA, Granada, Spain, 16Instituto de Parasitología y Biomedicina ‘López-Neyra’, CSIC, PTS Granada, Spain, Granada, Spain, 17Instituto de Parasitología y Biomedicina ‘López-Neyra’, CSIC, PTS Granada, Granada, Spain, 18Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain

    Background/Purpose: Nephritis is the main cause of long-term morbidity and mortality in patients with Immunoglobulin-A vasculitis (IgAV) [1, 2]. Unfortunately, sensitive, specific, and non-invasive biomarkers…
  • Abstract Number: 0121 • ACR Convergence 2024

    Intra-renal Involvement in Primary Antiphospholipid Antibodies Syndrome: Data from Two Italian Centers

    Liala Moschetti1, Savino Sciascia2, Micaela Fredi3, Mattia Zappa4, Massimo Radin5, Ilaria Cavazzana3, Stefania Affatato6, Cecilia Nalli7, Laura Andreoli8, Federico Alberici9, Franco Franceschini1, Dario Roccatello10 and Angela Tincani11, 1Scleroderma Unit, Rheumatology and Clinical Immunology Unit, ERN ReCONNET, ASST Spedali Civili, Brescia, Italy, Brescia, Italy, 2University of Turin, Torino, Turin, Italy, 3Rheumatology and Clinical Immunology Unit and Department of Clinical and Experimental Sciences, ERN ReCONNET; ASST Spedali Civili and University of Brescia, Italy, Brescia, Italy, 4Nephrology Unit and Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health; ASST Spedali Civili and University of Brescia, Italy, Brescia, Italy, 5University of Turin, Turin, Italy, 6Nephrology Unit, University of Brescia, ASST Spedali Civili, Brescia, Italy, Brescia, Italy, 7ASST SPEDALI CIVILI DI BRESCIA, Brescia, Italy, 8University of Brescia, Brescia, Italy, 9Nephrology Unit, ASST Spedali Civili di Brescia, Brescia, Italy, 10Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID) and Department of Clinical and Biological Sciences; San Giovanni Bosco Hospital and University of Turin, Italy, Turin, Italy, 11ASST Spedali Civili-University of Brescia, Brescia, Italy

    Background/Purpose: Antiphospholipid antibodies nephropathy (aPL-N) is defined by thrombotic microangiopathy (TMA) early lesions and late lesions such fibro-intimal hyperplasia with luminal obliteration/organized thrombi, fibrous arterial/arteriolar…
  • Abstract Number: 2505 • ACR Convergence 2024

    C5 Signaling Pathway Genes as Key Drivers of the Pathogenesis of IgA Vasculitis?

    Joao Carlos Batista-Liz1, Vanesa Calvo-Rio2, María Sebastián Mora-Gil3, Ligia Gabrie-Rodriguez4, Rafael Gálvez Sánchez4, Belén Sevilla-Pérez5, José Luis Callejas6, María Teresa Leonardo7, Ana Peñalba7, Javier Narvaez-García8, Luis Martín-Penagos9, Luis Caminal-Montero10, PAZ COLLADO11, Patricia Quiroga Colina12, Esther Vicente-rabaneda13, Esteban Rubio14, Manuel León Luque15, Juan María Blanco-Madrigal16, Eva Galindez-Agirregoikoa17, Santos Castañeda13, Ricardo Blanco-Alonso18, Veronica Pulito-Cueto1 and Raquel Lopez-mejias1, 1IDIVAL, Santander, Spain, 2Valdecilla Hospital, Santander, Cantabria, Spain, 3Immunopathology Group, IDIVAL, Santander, Spain, 4Immunopathology Group, IDIVAL. Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 5Division of Pediatrics, Hospital Universitario San Cecilio, Granada, Spain, 6Systemic Autoimmune Diseases Unit, Hospital Clinico San Cecilio, Instituto de Investigación Biosanitaria de Granada ibs.GRANADA, Granada, Spain, 7Division of Pediatrics, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 8Hospital Universitario de Bellvitge, Barcelona, Spain, 9Immunopathology Group, IDIVAL. Division of Nephrology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 10Internal Medicine Department, Hospital Universitario Central de Asturias, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain, 11Hospital Universitario Severo Ochoa, MADRID, Spain, 12Division of Rheumatology, Hospital Universitario de La Princesa, Madrid, Spain, 13Hospital Universitario de La Princesa, Madrid, Spain, 14Division of Rheumatology, Hospital Universitario Virgen del Rocío, Sevilla, Spain, Sevilla, Spain, 15Division of Rheumatology, Hospital Universitario Virgen del Rocío, Sevilla, Spain., Sevilla, Spain, 16Division of Rheumatology, Hospital Universitario de Basurto, Bilbao, Spain., Bilbao, Spain, 17BASURTO UNIVERSITY HOSPITAL, BILBAO, Spain, 18Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain

    Background/Purpose: Immunoglobulin A Vasculitis (IgAV) is an inflammatory disease caused by the accumulation of immune complexes of IgA in the walls of small blood vessels…
  • 1
  • 2
  • 3
  • …
  • 5
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology